thoughts on these estimates, before EPS results? Acasti Pharma Inc (NASDAQ:ACST)

0
41

Earnings results for Acasti Pharma Inc (NASDAQ:ACST)

Estimate Momentum measures change in analyst sentiment over time and may be an indicator of future price movements. The Change in Consensus chart shows the current, 1 week ago, and 1 month ago consensus earnings per share (EPS*) forecasts. For the fiscal quarter endingMar 2020 , the consensus EPS* forecast has remained the same over the past week at -0.09 and remained the same over the past month at -0.09. none raised and none lowered their forecast. For the fiscal year ending Mar 2020 , the consensus EPS* forecast has remained the same over the past week at -0.42 and remained the same over the past month at -0.42 . none raised and none lowered their forecast.

Analyst Opinion on Acasti Pharma Inc (NASDAQ:ACST)

6 Wall Street analysts have issued ratings and price targets for Acasti Pharma in the last 12 months. Their average twelve-month price target is $4.19, suggesting that the stock has a possible upside of 655.26%. The high price target for ACST is $7.00 and the low price target for ACST is $2.00. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of “Buy.”

Acasti Pharma has received a consensus rating of Buy. The company’s average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings. According to analysts’ consensus price target of $4.19, Acasti Pharma has a potential upside of 655.3% from its current price of $0.56. Acasti Pharma has only been the subject of 2 research reports in the past 90 days.

Dividend Strength: Acasti Pharma Inc (NASDAQ:ACST)

Acasti Pharma does not currently pay a dividend. Acasti Pharma does not have a long track record of dividend growth.

Insiders buying/selling: Acasti Pharma Inc (NASDAQ:ACST)

In the past three months, Acasti Pharma insiders have not sold or bought any company stock. Only 1.78% of the stock of Acasti Pharma is held by institutions.

Earnings and Valuation of Acasti Pharma Inc (NASDAQ:ACST

Earnings for Acasti Pharma are expected to grow in the coming year, from ($0.42) to ($0.41) per share. The P/E ratio of Acasti Pharma is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Acasti Pharma is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Acasti Pharma has a P/B Ratio of 3.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

More latest stories: here